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1, INTRODUCTION 
The human insulin-like growth FXCOr-I (IGF-I) gene 
is composed of at least 5 e~ons located over 85 kb on 
chromosome 12 [l-lo]. Recent studies have revealed 
that the IGF-I gene codes for two mRNA transcripts, 
IGF-IA and IGF-IB mRNAs, formed by alternative 
splicing [I ,7-lo], IGF-IA mRNA (rcprcsentingexons I, 
II, III and V) codes for a 175kDa protein of 153 amino 
acids, whereas IGF-IB mRNA @presenting exons I, II, 
III and IV) codes for a 21 .&kDa protein of 195 amino 
acids [1,7-lo]. Although IGF-IA and IGF-IB mRNAs 
have been identified, neither protein has yet been 
isolated and characterized, In contrast, the serum form 
of XGF-I, referred to as somatomedin C, is known to be 
a 7.6.kDa molecule of 70 amino acids, which is coded 
for by the sequences in exons II and III of the IGF-I 
gene, and is probably formed from the proteolytiz 
cleavage of larger precursor proteins directed by IGF- 
IA and/or IGF-IB mRNA transcripts [1,7-103. It is 
becoming evident hat the tissue forms of IGF-H with a 
molecular mass of 18-25 kDa are produced by liver, 
alveolar macrophages, and fibroblasts [11-132. 
However, the expression of IGF-IA and IGF-II3 mRNA 
transcripts in these cells has not been examined and the 
relationship of the tissue IGF-I molecules to the 
putative protein products of IGF-IA and IGF-IB 
mRNA transcripts is not clear. 
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In this study, therefore, we have evaluated the cx- 
prcssion of IGF-IA and IGF-IB mRP4A transcripts in 
liver, hrpatoma cells, macrophage-like cells and 
fibroblasts, and found that these: cells express both 
IGF-IA and B mRNA transcripts, but IGF-IA mRNA is 
IO-fold more abundant, 
2. MATERIALS AND METHODS 
HUH-7 (human hcpatomn cell line, JCRn0403) and SF-TY (human 
skin fibroblasts, JCRB007S) were obtained from the Jepancsc Cancer 
Research Resources Bank (JCRB, Tokyo). U937 (human 
macropllagc-likcccll line, CRLlS93) was obtained from the American 
Type Culture Collection (Rockvillr, MD). Normal human liver was 
obtnined at a post-mortem examination, In sonic experiments, 
MRC.9 (human lung fibroblasts, CCL212) obtained from JCRB and 
human alveolar macrophagcs (>90% pure) obtained by bron- 
choalvcolar lavayc [14] were also used. 
2.2, Evaluurion of IGF-IA ctnd B trrRNA rranscri,ots by reverse 
lrutlscri~lion.l)olytt~erQs~~ chain reocrion (RT-PCR) 
Total cellular RNA was isolated by the acid guanidinium- 
thiocyanate-phenol-chloroform extraction method [IS]. First strand 
cDNA was synthesized from total cellular RNA by M-MLV reverse 
transcriprase (BRL, Gaithersburg, MD) using oligo-dT as a primer. 
Aliquots of the resulting reaction mixtures were used as templates for 
amplification by the polymerasc chain reaction using Thermus 
quaricus DNA polymerase, a thermal cycler (Pcrkin-Elmer Cetus In- 
struments, Norwalk, CT) and exon-specific oligonucleotide extension 
primers based on the nucleotide sequences of IGF-IA and IGF-ID 
cDNAs [7,8,16]. Primers for &F-IA; exon I primer (20.mer) cor- 
responding to the sequences of IGF-IA cDNA 72-91 (81 and exon V 
primer (20.mer) corresponding to the sequences of IGF-IA cDNA 
639-658 [El; primers for IGF-113, exon 1 primers, the same primer us- 
cd for IGF-IA cDNA, but corresponding to the sequences of IGF-18 
cDNA 90-109 [7] and exon IV primer (20smer) corresponding to the 
sequences of IGF-IB cDNA 921-940 [7]. The reaction was carried out 
in a SO pl volume under recommended conditions for 30 cycles, each 
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Fig. 1. identification of IGF-IA and IGF-IB mRNA transcripts by RT-PCR, (A) Schematic representation of the human IGF-I gene and the 
strategy for identifying IGF-IA and IGF-IB mRNA transcripts by RT-PCR. The human IGF-I gene has at least § coding exons, but the complete 
structure of the 5’ portion of exon I (and/or the existence of additional 5’ exons) is unknown. The putative start codon (ATG) is in exon I. There 
are two in-phase stop codons (TGA in exon IV, TAG in exon V). IGF-I mRNA precursor is processed into IGF-IA mRNA (represcr&ua cxons 
1, II, III and V) and IGF-IE mRNA (representing exons !r !II 111 and IV) through alternative splicing. After IGI:-IA and IGF-IB cDNAs were syn- 
thesized by reverse transcription, cDNAs were amplified by PCR using ICF-I exon-specific primers (exon I, exon IV and exon V primers). The 
expected sizes of amplified cDNAs were 587 bp and 851 bp for IGF-IA and IGF-I5 mRNAs, respectively. (B) Agarose gel electrophoresis analysis 
of amplified cDNA. After cDNAs from liver, HUH-7 hepatoma cells, U937 macrophage-like cells and SF-TY fibroblnsts were amplified, DNAs 
were analyzed on 1% agarose gel. Left lanes: cDNGs amplified with exon I and axon V primers (corresponding to IGF-IA mRNA); right lanes: 
cDNAs amplified with exon I and exon IV primers (corresponding to IGF-EB mRNA). ~X174/tiaeill digest fragments were used as markers. 
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Fig. 2. Quantificntien uf IGFslA nnd IGWR mRNh trWxriptr by n aelirtiun Iryhritliantianrl\Nnxc prutcrtian ;iwry. (A) IGF-IA nnd IGF4B 
mlZN.A tmnrcripte, nnd ICiF:-I sson+,pccific cRNA probes, The ICil~~IA~spccit’ir antiwise eRNA probe conlisted of 5117 bares spanning cxons I, 
II, III and V. The ICiI:-ID-rpccific antisctw cRNh probe sunristcd of 851 twcx rpannitry cxunr I, II, III and IV, The rcrtwnrcs of both cHNA 
prober spanning CSOIIS I, II and III (495 bares) are rhr same and common to both KWIA and tGF.IO tnRNAs. (B) Evaluation of &F-IA and 
ICiF-ID mRNh transcripts by an RNasc protection assay, Ttml ssllulnr RNAs (10 pp) from liver, WU?+-7 hcpatoma cells, UO37 marraphngc~likc 
cells at\tl SF*TY fibrobktstd were hybridized with “‘P-labclcld lGF~lh.rpccific cRNA prnbc (let? Iarm) and IGF-I Wspccific cRNA probe (right 
klrlcs)~ “P-Labslcd ~$XI74/Wwlll digest fragments wcrc usrtl as markers. 
fibroblasts yielded both 587 bp and 851 bp amplified 
cDNAs (Fig. 1B). The nucleotidc sequences of the 
amplified cDNAs were examined, and proved co be 
ider;ticai to those of IGF-IA and IGF-IB cDNAs 
reported [7-91 (data not shown). These observations in- 
dicate that these cells express both IGF-IA and B 
mRNA transcripts. 
Next, the amounts of IGF-IA and IGF-IB mRNA 
were quantified using a solution hybridization/RNase 
protection assay. Hybridization of IGF-IA-specific pro- 
be with cellular R.NA would bc expected to result in the 
appearance of protected bands of 587 bases (correspon- 
ding to IGF-IA mRNA) and 495 bases (corresponding 
to exons I, II, III of IGF-IB mRNA), and hybridization 
of IGF-ISspecific probe with cellular RNA would be 
expected to result in the appearance of protected bands 
of 85 1 bases (corresponding to IGF-II3 mRNA) and 495 
bases (corresponding to exons I, II, III of IGF-IA 
mRNA) (Fig. 2%). Figure 2B shows the results of the 
hybridization of these two probes with total cellular 
RNA from various cells. IGF-IA and IGF-IB mRNAs 
were present in these cells, and IGF-IA mRNA was the 
predominant species. The quantification of the levels of 
ICC-IA and IGF-IB mRNAs by densitometry 
demonstrated that IGF-IA mRNA was lo-fold more 
abundant than IFG-IB mRNA in each case, although 
the amounts of both mRNAs were different among 
these cells (Table I). ICF-IA mRNA was also more 
abundant than IGF-I5 mRNA in human alvcular 
tnarrophages and another cell line of fibroblasts, 
MRC-9 (Table I). Thus, IGF-IA mRNA was the 
predominant species in all cells examined. 
It is possible that the low abundance of IGF-IB 
mRNA relative to IGF-IA mRNA is due to the instabili- 
ty of IGF-II3 mRNA. To confirm this possibility the 
stabilities of IGF-IA and IGF-IB mRNA were examined 
(Fig. 3). In the absence of actinomycin D, a transcrip- 
tion inhibitor, IGF-IA and IGF-IB mRNA levels were 
Table I 
Quatitification of IGF-IA and IGF-IB mRNA transcripts 
IGF-IA mRNA IGF-ID mRNA 
Liver 0.306 1 0.075 0,027 f 0.006 
HUH-7 hepatoma cells 0.183 I?- 0.057 0.018 f 0.005 
U937 macrophageJike cells 0.150 :t 0.035 0.011 rt: 0.003 
Alveolar macrophages 0.203 rt 0.056 0.020 :t 0.008 
SF-TY fibroblasts 0.051 zt 0.026 0.004 f 0,002 
MRC-9 fibroblasts 0.061 k 0.015 0.006 f 0.001 
. ..- 
The autoradiographic signals were quantified by densitometry. The 
amounts of IGF-IA and IGF-IB mRNAs expressed as pg/pg total 
cellular RNA were calculated using standard curves constructed with 
various quantities of synthetic unlabeled IG&IA and IGF-IB sense 
cRNAs, Values represent the mean rt SE of 3 experiments. 
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Fig. 3. Slabilitisx of IGF.IA and IGF-IB nrRNA transcript% MUl1.7 
hcpnmnia cclk, U937 macrophagc.likc cc111 and SF-TY fibrobtnsls 
were incubated in the absence ( - hcliiiomycin D) or prcscncc (+ At- 
tinomycin D)of tO&ml actinurnycin D for up to 24 h. Arrcr the in. 
cubation, rotnl cellular RNA was irota~cd and lhc amaunrs of IGF.IA 
(0) and IGF-IB (*) mRNAs were quantified by a salurion hybridiza. 
tion/RNasc protection rr..,;j. tGF-I mRNA levels arc cxprcsrctl as a 
percentage of rnRNA kvcls in cells at zero time. Values rcprescnl [he 
mean * SE of 3 cspcrimeiits. 
not changed over 24 h. On the other hand, both IGF-I 
mRNA levels decreased in a time dependent manner in 
the presence of actinomycin I). Although the half-lives 
of both IGF-I mRNAs of hepatoma cells and 
macrophage-like cells were longer than those of 
fibroblasts, there was no difference in the stabilities of 
both IGF-IA and IGF-II3 mRNAs in each case. 
Moreover, the half-lives of IGF-IA and IGF-IB 
mRNAs were not different in alveolar macrophages and 
MRC-9 fibroblasts (data not shown). These observa- 
tions indicate that IGF-IA mRNA is more expressed 
A. Cont3en~3us sequence G U ~AGU--- 
B. IGF-6 mRNA prrcussos 
Exons 1-X.X GUAAAU--- 
Exons II-fI.I GUAAGU--- 
mon5 III-IV GUAAGC--- 
EIsona IV-V UUAAGC--- 
Fig, 4. The S ‘-splice junction sequences of the human IGF-I mRNA 
precursor. The consensus sequence of intron at the 5’ splice site (A) 
[ZO] and the sequences of introns at the 5’ splice sites of the human 
IGF-I mRNA precursor (B) [9] are shown, The variation from the 
5’.consensus GU dinucleotide sequence is underlined. 
The mccknniam govcrnint: rhc prcdominnnt cxprex- 
sion of IGF-IA mRNA in not clc~. Hcrw~er, it ia 
known thai the conzlcnsus xequcnces which arc present 
at rhc csoniintran bsuntlarics of mRNA prccurtara 
plny an important rule in splicing (20-241. Murations in 
the splice junction sequences arc reported to interfere 
with mRNA pt-cc~tr%ar spliciny, e.g. murntianr in the 
GU tlinuclruticlc at the 5’ splice site reduce the pracluc- 
tion of correctly spliced mRNA, an<! insrrad promote 
the production af aberrantly spliced mRNh by tlreexci- 
sion of the cxcm present UpStWi~lll of the mutation 
through altcrnnrivc spliciny [24,25], Mutations in the 
polypyrimidinc tract at the 3’ splice site rnnrkcdly 
rcducc the efficiency of the splicing [21,26]. Intercscing- 
ly, the 5’ GU dinucleotidc is replaced by UU in the in- 
tron bctwcen won IV and exon V of the IGF-I mRNA 
precursor (Fig, il). This variation from the 5’.co~~scnsus 
sequence may reduce the splicing of cxon IV to eXon V 
and promote the ‘aberrant’ joining of cxon III to cxon 
V, resulting in the predolninant production of IGF-IA 
mRNA. However, detailed mechanisms controlling the 
splicing of the IGF-I mKNA precursor emain to be 
elucidated in the future. 
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